New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
09:00 EDTPBYIPuma Biotechnology falls 10.7%
Puma Biotechnology is down 10.7%, or $8.18, to $68.25
News For PBYI From The Last 14 Days
Check below for free stories on PBYI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2014
07:12 EDTPBYIPuma Biotechnology neratinib use unlikely to be limited, says Citigroup
Although Puma's Neratinib breast cancer drug was enriched for high risk HER2+ patients during a recent trial, Citigroup does not expect its use to be restricted to high risk women. The firm keeps a $292 price target and Buy rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use